Protective Antibody Level After COVID-19 Vaccination Among Patients Under Hemodialysis

N/ACompletedNCT04871945

Hanyang University Seoul Hospital31 enrolled

Overview

The aim of the study is to evaluate the level of neutralizing antibody against SARS-CoV-2 after COVID-19 vaccination in patients under hemodialysis. To this end, the level of neutralizing antibody of patients under hemodialysis is compared to that of healthy population.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Covid19 Vaccine Reaction Hemolysis End-stage Renal Disease

Interventions

Elecsys Anti-SARS-CoV-2 S (Roche Diagnostics GmbH, Mannheim, Germany), 2) ACCESS SARS-CoV-2 IgG II (Beckman Coulter, Inc. USA)DIAGNOSTIC_TEST

The antibody level will be measured by the above mentioned methods. The trial drugs are not used but the vaccine that included in National Immunization Program for COVID-19 in Korea will be used for the study.

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * The person who is vaccinated with ChAdOx1 (COVID-19 vaccine) * The person who agrees with the protocol of the study Exclusion Criteria: * Age \< 18 years * Pregnants * Experience of COVID-19 infection

Locations (1)

Hanyang University Seoul Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

The change in the level of neutralizing antibody against SARS-CoV-2

Time frame: Day 0, 14, 28, 56, 91, 120

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.